There were no clinically relevant modifications when compared with 2011 apart from new info and new suggestions regarding the remedy with bisphosphonates and denosumab (see segment ‘Bisphosphonates and RANKL Antibody Denosumab’).Mainly because of the available proof, the ASCO encouraged as early as 2021 that any axillary intervention – which … Read More